Startups: Shire on the lookout for rare disease acquisitions
Shire will likely continue its pursuit of rare disease acquisitions, as CEO Flemming Ornskov hinted at during its latest earnings call. The Irish pharma giant, known largely for its ADHD pipeline, is now focusing in on a rare disease market.